drugset / Trial / NCT05620498
Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an Open Phase II Clinical Study of Tislelizumab Combined with Lenvatinib and GEMOX Versus Tislelizumab Combined with GEMOX in the Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer.
Timeline
- Start
- 2022-09-08
- Primary completion
- 2023-06-30
- Completion
- 2024-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 4 mg | Oral |
| Subject | Lenvatinib | Small molecule | 8 mg/kg | Oral |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 100 mg/m2 | — |
| Background | Tislelizumab | Monoclonal antibody | 200 mg | — |